HomeComparePFE vs RS

PFE vs RS: Dividend Comparison 2026

PFE yields 6.20% · RS yields 1.61%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RS wins by $5.88M in total portfolio value
10 years
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →
RS
RS
● Live price
1.61%
Share price
$300.49
Annual div
$4.85
5Y div CAGR
90%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.93M
Annual income
$4,946,851.97
Full RS calculator →

Portfolio growth — PFE vs RS

📍 RS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPFERS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PFE + RS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PFE pays
RS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
RS
Annual income on $10K today (after 15% tax)
$137.19/yr
After 10yr DRIP, annual income (after tax)
$4,204,824.17/yr
At 15% tax rate, RS beats the other by $4,181,695.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PFE + RS for your $10,000?

PFE: 50%RS: 50%
100% RS50/50100% PFE
Portfolio after 10yr
$2.99M
Annual income
$2,487,031.25/yr
Blended yield
83.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
RS
Analyst Ratings
9
Buy
16
Hold
2
Sell
Consensus: Hold
Price Target
$330.00
+9.8% upside vs current
Range: $320.00 — $340.00
Altman Z
6.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PFE buys
0
RS buys
0
No recent congressional trades found for PFE or RS in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPFERS
Forward yield6.20%1.61%
Annual dividend / share$1.72$4.85
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR13.2%90%
Portfolio after 10y$51.1K$5.93M
Annual income after 10y$27,210.54$4,946,851.97
Total dividends collected$60.1K$5.83M
Payment frequencyquarterlyquarterly
SectorHealthcareMaterials
Analyst consensusHoldHold
Analyst price target$27.50$330.00

Year-by-year: PFE vs RS ($10,000, DRIP)

YearPFE PortfolioPFE Income/yrRS PortfolioRS Income/yrGap
1← crossover$9,161$701.38$11,007$306.67$1.8KRS
2$8,610$859.79$12,376$599.36$3.8KRS
3$8,366$1,081.25$14,440$1,196.75$6.1KRS
4$8,483$1,405.66$17,930$2,479.30$9.4KRS
5$9,084$1,907.24$24,651$5,466.60$15.6KRS
6$10,418$2,732.78$39,723$13,346.12$29.3KRS
7$13,007$4,193.56$80,692$38,188.01$67.7KRS
8$18,010$7,005.87$224,087$137,747.25$206.1KRS
9$28,216$12,979.89$919,042$679,268.17$890.8KRS
10$51,081$27,210.54$5,930,227$4,946,851.97$5.88MRS

PFE vs RS: Complete Analysis 2026

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →

RSMaterials

Reliance Steel & Aluminum Co. operates as a diversified metal solutions provider and the metals service center company in the United States, Canada, and internationally. The company distributes a line of approximately 100,000 metal products, including alloy, aluminum, brass, copper, carbon steel, stainless steel, titanium, and specialty steel products; and provides metals processing services to general manufacturing, non-residential construction, transportation, aerospace, energy, electronics and semiconductor fabrication, and heavy industries. It also distributes non-ferrous metals products and tubular building products; and manufactures specialty extruded metals, fabricated parts, and welded components. As of December 31, 2021, the company operated a network of approximately 315 locations in 40 states in the United States and 13 in other countries. It sells its products directly to original equipment manufacturers, which primarily include small machine shops and fabricators. The company was founded in 1939 and is headquartered in Los Angeles, California.

Full RS Calculator →
📬

Get this PFE vs RS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PFE vs JNJPFE vs MRKPFE vs ABBVPFE vs BMYPFE vs LLYPFE vs SCHDPFE vs JEPIPFE vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.